

## NEWS & VIEWS REFERENCES

### Metformin reduces COVID severity in prediabetes.

1. Chan LE, Casiraghi E, Laraway B, Coleman B, Blau H, Zaman A, Harris N, Wilkins K, Gargano M, Valentini G, Sahner D, Haendel M, Robinson PN, Bramante C, Reese J. Metformin is Associated with Reduced COVID-19 Severity in Patients with Prediabetes. medRxiv 2022.08.29.22279355; doi: <https://doi.org/10.1101/2022.08.29.22279355>

### SGLT2-i for heart failure and kidney disease

1. Williams DL, Rofail S, Atherton JJ. Sodium-glucose co-transporter 2 inhibitors beyond diabetes. Aust Prescr 2022;45:121-4. <https://doi.org/10.18773/austprescr.2022.036>
2. SGLT2 inhibitors for heart and kidney disease. NPS MedicineWise podcast Episode 139. Accessed 19 September, 2022 at <https://www.nps.org.au/australian-prescriber/podcast/episode-139-sgl2-inhibitors-for-heart-and-kidney-disease>

### Diabetes rates in Australia tripled in the past 20 years

1. Australian Institute of Health and Welfare (2022) Diabetes: Australian facts, AIHW, Australian Government, accessed 16 September 2022.

### Dulaglutide injections for youth with T2D

1. Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, Bismuth E, Dib S, Cho JI, Cox D *et al.* for the AWARD-PEDS Investigators, Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med 2022; 387:433-443 DOI: 10.1056/NEJMoa2204601

### Do not to start patients on semaglutide or dulaglutide

1. <https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/ozempic-semaglutide-shortage>
2. <https://www.tga.gov.au/safety/shortages/medicine-shortage-alerts/trulicity-dulaglutide-shortage>
3. <https://www1.racgp.org.au/news/gp/clinical/semaglutide-unavailable-in-australia-until-april-2>

### Weight loss with semaglutide in East Asian people

1. Alabduljabbar K, Al-Najim W, le Roux CW. The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. Nutrients. 2022; 14(11):2217. <https://doi.org/10.3390/nu14112217>
2. Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. doi: 10.1016/S2213-8587(22)00008-0. Epub 2022 Feb 4. PMID: 35131037.
3. Grossman M, Semaglutide in east Asian overweight/obese adults. Diabetes Research Review Sept 2022; 133:5

## FEATURE REFERENCES

### p10-14 Metformin use in pregnancy

1. Group HSCR, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, *et al.* Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991-2002.
2. National Institute for Health and Care Excellence: Guidelines. Diabetes in pregnancy: management from preconception to the postnatal period. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2020.; 2020.
3. Rudland VL, Price SAL, Hughes R, Barrett HL, Lagstrom J, Porter C, *et al.* ADIPS 2020 guideline for pre-existing diabetes and pregnancy. Aust N Z J Obstet Gynaecol. 2020;60(6):E18-e52.

**p10-14 Metformin use in pregnancy – Cont'd**

4. Ministry of Health. 2014. Diabetes in Pregnancy: Quick reference guide for health professionals on the screening, diagnosis and treatment of gestational diabetes in New Zealand. Wellington: Ministry of Health.
5. Feig DS, Berger H, Donovan L, Godbout A, Kader T, Keely E, et al. Diabetes and Pregnancy. *Can J Diabetes*. 2018;42 Suppl 1:S255-s82.
6. Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. *Ther Drug Monit*. 2006;28(1):67-72.
7. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. *Fertil Steril*. 2006;86(3):658-63.
8. Panchaud A, Rousson V, Vial T, Bernard N, Baud D, Amar E, et al. Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. *Br J Clin Pharmacol*. 2018;84(3):568-78.
9. Scherneck S, Schlinke N, Beck E, Grupe K, Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. *Reprod Toxicol*. 2018;81:79-83.
10. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, Mi GTI. Metformin versus insulin for the treatment of gestational diabetes. *N Engl J Med*. 2008;358(19):2003-15.
11. Tarry-Adkins JL, Aiken CE, Ozanne SE. Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: A systematic review and meta-analysis. *PLoS Med*. 2019;16(8):e1002848.
12. Zhu B, Zhang L, Fan YY, Wang L, Li XG, Liu T, et al. Metformin versus insulin in gestational diabetes mellitus: a meta-analysis of randomized clinical trials. *Ir J Med Sci*. 2016;185(2):371-81.
13. Zhao LP, Sheng XY, Zhou S, Yang T, Ma LY, Zhou Y, et al. Metformin versus insulin for gestational diabetes mellitus: a meta-analysis. *Br J Clin Pharmacol*. 2015;80(5):1224-34.
14. Mesdaghinia E, Samimi M, Homaei Z, Saberi F, Moosavi SG, Yaribakht M. Comparison of newborn outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a randomised blinded trial. *Int J Prev Med*. 2013;4(3):327-33.
15. Tertti K, Ekblad U, Koskinen P, Vahlberg T, Ronnema T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. *Diabetes Obes Metab*. 2013;15(3):246-51.
16. Brown J, Martis R, Hughes B, Rowan J, Crowther CA. Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes. *Cochrane Database Syst Rev*. 2017;1:CD011967.
17. Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. *PLoS One*. 2013;8(5):e64585.
18. de Wit L, Rademaker D, Voormolen DN, Akerboom BMC, Kiewiet-Kemper RM, Soeters MR, et al. SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial. *BMJ Open*. 2019;9(8):e029808.
19. Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E, Ryan EA, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2020;8(10):834-44.
20. Benham JL, Donovan LE, Yamamoto JM. Metformin in Pregnancy for Women with Type 2 Diabetes: a Review. *Curr Diab Rep*. 2021;21(10):36.
21. Romero R, Erez O, Hüttemann M, Maymon E, Panaitescu B, Conde-Agudelo A, et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. *Am J Obstet Gynecol*. 2017;217(3):282-302.
22. Sacco F, Calderone A, Castagnoli L, Cesareni G. The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug. *Br J Cancer*. 2016;115(12):1451-6.
23. Barbour LA, Scifres C, Valent AM, Friedman JE, Buchanan TA, Coustan D, et al. A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. *Am J Obstet Gynecol*. 2018;219(4):367 e1- e7.
24. NCT01832181. MiTy Kids (Metformin in Women With Type 2 Diabetes in Pregnancy Kids Trial). <https://clinicaltrials.gov/ct2/show/NCT01832181>.
25. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. *Diabetes Care*. 2011;34(10):2279-84.

## November 2022 References

### p10-14 Metformin use in pregnancy – Cont'd

26. Rowan JA, Rush EC, Plank LD, Lu J, Obolonkin V, Coat S, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. *BMJ Open Diabetes Res Care*. 2018;6(1):e000456.
27. Hanem LGE, Salvesen O, Juliusson PB, Carlsen SM, Nossum MCF, Vaage MO, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. *Lancet Child Adolesc Health*. 2019;3(3):166-74.
28. Paavilainen E, Tertti K, Nikkinen H, Veijola R, Vaarasmaki M, Loo BM, et al. Metformin versus insulin therapy for gestational diabetes: Effects on offspring anthropometrics and metabolism at the age of 9 years: A follow-up study of two open-label, randomized controlled trials. *Diabetes Obes Metab*. 2022;24(3):402-10.
29. Aboelfath AaSEd, M. Predictive Factors of Successful Treatment of Gestational Diabetes with Metformin Monotherapy. *Open Journal of Obstetrics and Gynecology*. 2020;10, 1036-1044.
30. Khin MO, Gates S, Saravanan P. Predictors of metformin failure in gestational diabetes mellitus (GDM). *Diabetes Metab Syndr*. 2018;12(3):405-10.
31. Gante I, Melo L, Dores J, Ruas L, Almeida MDC. Metformin in gestational diabetes mellitus: predictors of poor response. *Eur J Endocrinol*. 2018;178(1):129-35.
32. McGrath RT, Glastras SJ, Hocking S, Fulcher GR. Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. *Diabetes Res Clin Pract*. 2016;116:96-9.
33. Benido Silva V, Fonseca L, Pereira MT, Vilaverde J, Pinto C, Pichel F, et al. Predictors of metformin monotherapy failure in gestational diabetes mellitus. *Endocr Connect*. 2022;11(5).
34. Horta BL, Loret de Mola C, Victora CG. Long-term consequences of breastfeeding on cholesterol, obesity, systolic blood pressure and type 2 diabetes: a systematic review and meta-analysis. *Acta Paediatr*. 2015;104(467):30-7.
35. Gunderson EP, Hurston SR, Ning X, Lo JC, Crites Y, Walton D, et al. Lactation and Progression to Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus: A Prospective Cohort Study. *Ann Intern Med*. 2015;163(12):889-98.
36. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Metformin. [Updated 2022 Mar 21]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501020/s>.
37. Kumar P, Khan K. Effects of metformin use in pregnant patients with polycystic ovary syndrome. *J Hum Reprod Sci*. 2012;5(2):166-9.
38. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. *Hum Reprod Update*. 2006;12(6):673-83.
39. Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. *Hum Reprod Update*. 2014;20(5):656-69.
40. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. *Hum Reprod*. 2002;17(11):2858-64.
41. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. *Fertil Steril*. 2001;75(1):46-52.
42. Tan X, Li S, Chang Y, Fang C, Liu H, Zhang X, et al. Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. *Clin Invest Med*. 2016;39(4):E120-31.
43. Lovvik TS, Carlsen SM, Salvesen O, Steffensen B, Bixo M, Gomez-Real F, et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2019;7(4):256-66.
44. Queensland Clinical Guidelines. Gestational diabetes mellitus (GDM). Guideline No. MN21.33-V6-R26. Queensland Health. 2022. Available from: <http://health.qld.gov.au/qcg>.
45. Wensink MJ, Lu Y, Tian L, Shaw GM, Rizzi S, Jensen TK, et al. Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring : A Nationwide Cohort Study. *Ann Intern Med*. 2022;175(5):665-73.

**p16-20 Planning Pregnancy with pre-existing diabetes**

1. Chivese T, Hoegfeldt CA, Werfalli M, Yuen L, Sun H, Karuranga S, Li N, Gupta A, Immanuel J, Divakar H, Powe CE, Levitt NS, Yang X, Simmons D. IDF Diabetes Atlas: The prevalence of pre-existing diabetes in pregnancy - A systematic review and meta-analysis of studies published during 2010-2020. *Diabetes Res Clin Pract.* 2022 Jan;183:109049. doi: 10.1016/j.diabres.2021.109049. Epub 2021 Dec 6. PMID: 34883190.
2. Immanuel J, Flack J, Wong V, Yuen L, Eagleton C, Graham, D, Lagstrom J, Wolmarans L, Martin M, Cheung NW, Padmanaghan S, Rudland V, Ross G, Moses RG, Maple-Brown L, Fulcher I, Chemmanam J, Nolan CJ, Oats JNJ, Sweeting A, Simmons D. The ADIPS Pilot National Diabetes in Pregnancy Benchmarking Programme. *Int J Environ Res Public Health.* 2021 May 4;18(9):4899. doi: 10.3390/ijerph18094899. PMID: 34064492
3. Shand AW, Bell JC, McElduff A, Morris J, Roberts CL. Outcomes of pregnancies in women with pregestational diabetes mellitus and gestational diabetes mellitus; a population-based study in New South Wales, Australia, 1998-2002. *Diabetic medicine* 2008;25(6):708-15.
4. Lemaitre M, Ternynck C, Bourry J, Baudoux F, Subtil D, Vambergue A. Association Between HbA1c Levels on Adverse Pregnancy Outcomes During Pregnancy in Patients With Type 1 Diabetes. *J Clin Endocrinol Metab.* 2022 Feb 17;107(3):e1117-e1125. doi: 10.1210/clinem/dgab769. PMID: 34694409; PMCID: PMC8852207. Rudland VL, Price SAL, Hughes R, Barrett HL, Lagstrom J, Porter C, Britten FL, Glastras S, Fulcher I, Wein P, Simmons D, McIntyre HD, Callaway L. ADIPS 2020 guideline for preexisting diabetes and pregnancy. *Aust NZJ Obstet Gynaecol.* 2020 Dec;60(6):E18-E52.
5. Wahabi HA, Fayed A, Esmail S, Elmorshedy H, Titi MA, Amer YS, Alzeidan RA, Alodhayani AA, Saeed E, Bahkali KH, Kahili-Heede MK. Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and perinatal outcomes. *PloS one.* 2020 Aug 18;15(8):e0237571

**p22-25 Hospital specialists join the GP team: virtual clinics to manage T2D**

1. Chivese T, Hoegfeldt CA, Werfalli M, Yuen L, Sun H, Karuranga S, Li N, Gupta A, Immanuel J, Divakar H, Powe CE, Levitt NS, Yang X, Simmons D. IDF Diabetes Atlas: The prevalence of pre-existing diabetes in pregnancy - A systematic review and meta-analysis of studies published during 2010-2020. *Diabetes Res Clin Pract.* 2022 Jan;183:109049. doi: 10.1016/j.diabres.2021.109049. Epub 2021 Dec 6. PMID: 34883190.
2. Immanuel J, Flack J, Wong V, Yuen L, Eagleton C, Graham, D, Lagstrom J, Wolmarans L, Martin M, Cheung NW, Padmanaghan S, Rudland V, Ross G, Moses RG, Maple-Brown L, Fulcher I, Chemmanam J, Nolan CJ, Oats JNJ, Sweeting A, Simmons D. The ADIPS Pilot National Diabetes in Pregnancy Benchmarking Programme. *Int J Environ Res Public Health.* 2021 May 4;18(9):4899. doi: 10.3390/ijerph18094899. PMID: 34064492
3. Shand AW, Bell JC, McElduff A, Morris J, Roberts CL. Outcomes of pregnancies in women with pregestational diabetes mellitus and gestational diabetes mellitus; a population-based study in New South Wales, Australia, 1998-2002. *Diabetic medicine* 2008;25(6):708-15.
4. Lemaitre M, Ternynck C, Bourry J, Baudoux F, Subtil D, Vambergue A. Association Between HbA1c Levels on Adverse Pregnancy Outcomes During Pregnancy in Patients With Type 1 Diabetes. *J Clin Endocrinol Metab.* 2022 Feb 17;107(3):e1117-e1125. doi: 10.1210/clinem/dgab769. PMID: 34694409; PMCID: PMC8852207. Rudland VL, Price SAL, Hughes R, Barrett HL, Lagstrom J, Porter C, Britten FL, Glastras S, Fulcher I, Wein P, Simmons D, McIntyre HD, Callaway L. ADIPS 2020 guideline for preexisting diabetes and pregnancy. *Aust NZJ Obstet Gynaecol.* 2020 Dec;60(6):E18-E52.
5. Wahabi HA, Fayed A, Esmail S, Elmorshedy H, Titi MA, Amer YS, Alzeidan RA, Alodhayani AA, Saeed E, Bahkali KH, Kahili-Heede MK. Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and perinatal outcomes. *PloS one.* 2020 Aug 18;15(8):e0237571

**p27 – 29 Disability in people with diabetes**

1. Williams A. Disability rights, benefits, and support services sourcebook : basic consumer health information about different types of disabilities. Detroit, Michigan: Omnigraphics; 2020.
2. World Health Organisation and World Bank. World report on disability. 2011.

**p27 – 29 Disability in people with diabetes – Cont'd**

3. McAllister A. Mental illnesses are not an 'ideal type' of disability for disability income support: Perceptions of policymakers in Australia and Canada. *Scandinavian journal of public health*. 2020;48(4):452-9.
4. Okoro CA, Hollis ND, Cyrus AC, Griffin-Blake S. Prevalence of Disabilities and Health Care Access by Disability Status and Type Among Adults — United States, 2016. *MMWR Morbidity and mortality weekly report*. 2018;67(32):882-7.
5. McVilly K, McGillivray J, Curtis A, Lehmann J, Morrish L, Speight J. Diabetes in people with an intellectual disability: a systematic review of prevalence, incidence and impact. *Diabetic medicine*. 2014;31(8):897-904. Epub *Diabet. Med.* 31, 897-904 (2014).
6. United Nations. *Convention on Rights of People with Disabilities*. 2006.
7. Australian Institute for Health and Welfare. *People with Disability in Australia 2022: In brief*. Report. AIHW; 2022 catalogue number DIS 81.
8. Australian Human Rights Commission. *Face the facts: Disability Rights*. 2014.
9. Balogh RS, Lake JK, Lin E, Wilton A, Lunskey Y. Disparities in diabetes prevalence and preventable hospitalizations in people with intellectual and developmental disability: a population-based study. *Diabetic medicine*. 2015;32(2):235-42. Epub *Diabet. Med.* 32, 235- 242 (2015).
10. Vancampfort D, Schuch F, Van Damme T, Firth J, Suetani S, Stubbs B, et al. Prevalence of diabetes in people with intellectual disabilities and age- and gender-matched controls: A meta-analysis. *Journal of applied research in intellectual disabilities*. 2022;35(2):301-11.
11. Shireman TIPD, Reichard APD, Nazir NMBBSMPH, Backes JMPD, Greiner KAMDMPH. Quality of diabetes care for adults with developmental disabilities. *Disability and health journal*. 2010;3(3):179-85.
12. Fauth EB, Zarit SH, Malmberg B. Mediating relationships within the Disablement Process model: a cross-sectional study of the oldest-old. *European journal of ageing*. 2008 Sep;5(3):161. PubMed PMID: 28798570. Pubmed Central PMCID: PMC5546336. Epub 2008/09/02. eng.
13. Bianchi L, Zuliani G, Volpato S. Physical disability in the elderly with diabetes: epidemiology and mechanisms. *Curr Diab Rep*. 2013 Dec;13(6):824-30. PubMed PMID: 24026868. Epub 2013/09/13.
14. Youn HM, Choi D-W, Jang S-I, Park E-C. Disparities in diabetes-related avoidable hospitalization among diabetes patients with disability using a nationwide cohort study. *Scientific Reports*. 2022 2022/02/02;12(1):1794.
15. Cuypers M, Leijssen M, Bakker-van Gijssel EJ, Pouls KPM, Mastebroek MM, Naaldenberg J, et al. Patterns in the prevalence of diabetes and incidence of diabetic complications in people with and without an intellectual disability in Dutch primary care: Insights from a population-based data-linkage study. *Primary care diabetes*. 2021;15(2):372-7.
16. MacRae S, Brown M, Karatzias T, Taggart L, Truesdale-Kennedy M, Walley R, et al. Diabetes in people with intellectual disabilities: a systematic review of the literature. *Research in developmental disabilities*. 2015;47:352-74.
17. Diaz KM. Leisure-time physical activity and all-cause mortality among adults with intellectual disability: the National Health Interview Survey. *Journal of intellectual disability research*. 2020;64(2):180-4.
18. Hamzaid NH, O'Connor HT, Flood VM. Observed Dietary Intake in Adults with Intellectual Disability Living in Group Homes. *Nutrients*. 2019 Dec 22;12(1). PubMed PMID: 31877838. Pubmed Central PMCID: PMC7020024. Epub 2019/12/28.
19. Oppewal A, Hilgenkamp TIM. Is fatness or fitness key for survival in older adults with intellectual disabilities? *Journal of applied research in intellectual disabilities : JARID*. 2020 Sep;33(5):1016-25. PubMed PMID: 32168552. Pubmed Central PMCID: PMC7496297. Epub 2020/03/14. eng.
20. Lynch L, McCarron M, McCallion P, Burke E. Sedentary behaviour levels in adults with an intellectual disability: a systematic review protocol: *HRB Open Res*. 2021 Mar 29;3:57. doi: 10.12688/hrbopenres.13123.2. eCollection 2020.
21. Diaz KM. Physical Activity and Sedentary Behavior Among U.S. Children With and Without Down Syndrome: The National Survey of Children's Health. *American journal on intellectual and developmental disabilities*. 2020 May;125(3):230-42. PubMed PMID: 32357102. Epub 2020/05/02. eng.
22. Doherty AJ, Atherton H, Boland P, Hastings R, Hives L, Hood K, et al. Barriers and facilitators to primary health care for people with intellectual disabilities and/or autism: an integrative review. *BJGP Open*. 2020;4(3):bjgpopen20X101030.

**p27 – 29 Disability in people with diabetes – cont'd**

23. Tyrer F, Dunkley AJ, Singh J, Kristunas C, Khunti K, Bhaumik S, et al. Multimorbidity and lifestyle factors among adults with intellectual disabilities: a cross-sectional analysis of a UK cohort. *Journal of intellectual disability research : JIDR*. 2019 Mar;63(3):255-65. PubMed PMID: 30485584. Epub 2018/11/30. eng.
24. Tyrer F, Morriss R, Kiani R, Gangadharan SK, Rutherford MJ. Mortality disparities and deprivation among people with intellectual disabilities in England: 2000-2019. *Journal of epidemiology and community health*. 2022 Feb;76(2):168-74. PubMed PMID: 34244310. Epub 2021/07/11. eng.
25. Redquest B, Ahmed S, Balogh R, Lunskey Y. Preventing and Treating Diabetes in Canadian Adults With Intellectual and Developmental Disabilities. *Canadian journal of diabetes*. 2020 Mar;44(2):205-10. PubMed PMID: 31495711. Epub 2019/09/10. eng.
26. Taggart L, Truesdale M, Dunkley A, House A, Russell AM. Health Promotion and Wellness Initiatives Targeting Chronic Disease Prevention and Management for Adults with Intellectual and Developmental Disabilities: Recent Advancements in Type 2 Diabetes. *Current Developmental Disorders Reports*. 2018 2018/09/01;5(3):132-42.
27. Haas LB. Special Considerations for Older Adults With Diabetes Residing in Skilled Nursing Facilities. *Diabetes spectrum : a publication of the American Diabetes Association*. 2014 Feb;27(1):37-43. PubMed PMID: 26246754. Pubmed Central PMCID: PMC4522888. Epub 2014/02/01. eng.
28. Sheehy R. Diabetes Management in Aged Care Facilities: Meeting the Challenges. *Endocrinology Today*. 2015;4(5):15-20.
29. Dunning T, Duggan N, Savage S. The McKellar Guidelines for Managing Older People with Diabetes in Residential and Other Care Settings: Centre for Nursing and Allied Health Research. Deakin University and Barwon Health; 2014.
30. Idrees T, Castro-Revoredo IA, Migdal AL, Moreno EM, Umpierrez GE. Update on the management of diabetes in long-term care facilities. *BMJ open diabetes research & care*. 2022;10(4).
31. LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of Diabetes in Older Adults: An Endocrine Society\* Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2019;104(5):1520-74.
32. Royal Australasian College of General Practitioners. Management of type 2 diabetes A handbook for general practice Royal Australasian College of General Practitioners and Diabetes Australia; 2020.
33. National Diabetes Services Scheme. Aged care diabetes management practical handbook. 2020.
34. Sinclair AJ, Abdelhafiz AH, Forbes A, Munshi M. Evidence-based diabetes care for older people with Type 2 diabetes: a critical review. *Diabet Med*. 2019 Apr;36(4):399-413. PubMed PMID: 30411402. Epub 2018/11/10. eng.
35. Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. *JAMA : the journal of the American Medical Association*. 2016;315(10):1034-45.
36. Sinclair AJ, Gadsby R, Abdelhafiz AH, Kennedy M. Failing to meet the needs of generations of care home residents with diabetes: a review of the literature and a call for action. *Diabetic medicine*. 2018;35(9):1144-56.
37. Mañas LR, Rodríguez MC, Sinclair AJ. Management of diabetes in older adults. In: Michel J-P, Beattie BL, Martin FC, Walston J, editors. *Oxford Textbook of Geriatric Medicine*: Oxford University Press; 2017. p.0.
38. Farrer O, Yaxley A, Walton K, Miller M. A scoping review of best practice guidelines for the dietary management of diabetes in older adults in residential aged care. *Primary care diabetes*. 2019;13(4):293-300.
39. Hopkins R, Shaver K, Weinstock RS. Management of Adults With Diabetes and Cognitive Problems. *Diabetes spectrum : a publication of the American Diabetes Association*. 2016 Nov;29(4):224-37. PubMed PMID: 27899874. Pubmed Central PMCID: PMC5111537. Epub 2016/12/03. eng.
40. Organisation WH. Fact sheet: Disability and health. 2021 29 August 2022:3. Pubmed Central PMCID: 24 November 2021.
41. Nolan-Isles D, Macniven R, Hunter K, Gwynn J, Lincoln M, Moir R, et al. Enablers and Barriers to Accessing Healthcare Services for Aboriginal People in New South Wales, Australia. *International journal of environmental research and public health*. 2021 Mar 15;18(6). PubMed PMID: 33804104. Pubmed Central PMCID: PMC7999419. Epub 2021/04/04. eng.
42. Welfare AlfHa. Report: Diabetes and disability: impairments, activity limitations, participation restrictions, and comorbidities 2013 [cited 2013 29 August 2022].

## November 2022 References

### **p27 – 29 Disability in people with diabetes – Cont'd**

43. Adu MD, Malabu UH, Malau-Aduli AEO, Malau-Aduli BS. Enablers and barriers to effective diabetes self-management: A multi-national investigation. *PLoS One*. 2019;14(6):e0217771. PubMed PMID: 31166971. Pubmed Central PMCID: PMC6550406. Epub 2019/06/06. eng.
44. Whittemore R, Vilar-Compte M, De La Cerda S, Marron D, Conover R, Delvy R, et al. Challenges to diabetes self-management for adults with type 2 diabetes in low-resource settings in Mexico City: a qualitative descriptive study. *International Journal for Equity in Health*. 2019 2019/08/23;18(1):133.
45. Kelly J. Diabetes and Me: Learning disabilities and diabetes. *Journal of Diabetes Nursing*. 2011;15(8).

### **p30-31 Multidisciplinary student learning can help fill the health service gap**

1. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. *Nat Rev Nephrol*. [Internet]. 2016 Feb [cited 2021 Dec 22];12(2):73-81.
2. Zimbudzi E, Lo C, Marie L et al. Effectiveness of self-management support interventions for people with comorbid diabetes and chronic kidney disease: a systematic review and meta-analysis. *Systematic Reviews* [Internet]. 2018 Jun 1 [cited 2021 Dec 22];7(1):1–14.
3. Gregg EW, Sophiea MK, Weldegiorgis M. Diabetes and COVID-19: Population impact 18 months into the pandemic. *Diabetes care* [Internet]. 2021 Sep [cited 2021 Dec 22];44(9):1916–23.
4. Selvin E, Juraschek SP. Diabetes epidemiology in the COVID-19 pandemic. *Diabetes care* [Internet]. 2020 Aug [cited 2021 Dec 22];43(8):1690–4.
5. Musial J, Cawte A, Mullins R, Hannan-Jones M, de Jersey S. Implementation and evaluation of a university-hospital partnership program for Type 2 diabetes. *Australian health review* [Internet]. 2021 Nov 16 [cited 2021 Dec 22].
6. Berkowitz SA, Eisenstat SA, Barnard LS, Wexler DJ. Multidisciplinary coordinated care for Type 2 diabetes: A qualitative analysis of patient perspectives. *Prim Care Diabetes* [Internet]. 2018 Jun [cited 2021 Dec 22];12(3):218–23.
7. Navaneethan SD, Zoungas S, Caramori ML et al. Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. *Ann Intern Med* [Internet]. 2021 Mar [cited 2021 Dec 22];174(3):385–94.
8. Medicare Benefits Schedule: [Internet]. MBS online. [cited 2021 Dec 22].
9. Kumar S, Lensink IL, Turnbull C. Tips for using students during times of change in health care: lessons from the literature and from practice. *Adv Med Educ Pract* [Internet]. 2017 Jul 1 [cited 2021 Dec 22];ume 8:535–40.
10. Kent F, Martin N, L. Keating J. Interprofessional student-led clinics: An innovative approach to the support of older people in the community. *J Interprof Care* [Internet]. 2016 Jan [cited 2021 Dec 22];30(1):123–8.
11. Stuhlmiller CM, Tolchard B. Developing a student-led health and wellbeing clinic in an underserved community: collaborative learning, health outcomes and cost savings. *BMC Nursing* [Internet]. 2015 Jun [cited 2021 Dec 22];14(1):1–8.
12. Diabetes Victoria and the Victorian Aboriginal Community Controlled Health Organisation. Feltman and Feltmum. Order from <https://www.diabetesvic.org.au/feltman-order-form>

### **p32-34 Dietary Advanced Glycation End-products (AGEs) and metabolic health: delicious but dangerous**

1. Poulsen MW, Hedegaard RV, Andersen JM, et al. Advanced glycation end products in food and their effects on health. *Food Chem Toxicol* 2013; 60: 10–37.
2. Kellow NJ & Coughlan MT. Effect of diet-derived advanced glycation end products on inflammation. *Nutr Rev* 2015; 73(11): 737–759.
3. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. *J Am Diet Assoc* 2010; 110: 911–916.
4. Scheijen JLJM, Clevers E, Engelen L, et al. Analysis of advanced glycation end products in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: Presentation of a dietary AGE database. *Food Chem* 2016; 190: 1145–1150.
5. Maasen K, Scheijen JLJM, Opperhuizen A, et al. Quantification of dicarbonyl compounds in commonly consumed foods and drinks; presentation of a food composition database for dicarbonyls. *Food Chem* 2021; 339: 128063. doi: 10.1016/j.foodchem.2020.128063.
6. Tessier FJ, Boulanger E, Howsam M. Metabolic transit of dietary advanced glycation end-products - the case of Nε-carboxymethyllysine. *Glycoconj J* 2021; 38: 311–317.

**p32-34 Dietary Advanced Glycation End-products (AGEs) and metabolic health – Cont'd**

7. Hellwig M, Bunzel D, Huch M, *et al.* Stability of individual Maillard reaction products in the presence of the human colonic microbiota. *J Agric Food Chem* 2015; 63: 6723–6730.
8. Delgado-Andrade C, Tessier FJ, Niquet-Léridon C, *et al.* Study of the urinary and faecal excretion of Nε-carboxymethyllysine in young human volunteers. *Amino Acids* 2012; 43: 595–602.
9. Fotheringham AK, Gallo LA, Borg DJ, *et al.* Advanced Glycation End Products (AGEs) and chronic kidney disease: does the modern diet AGE the kidney? *Nutrients* 2022; 14: 2675.
10. Vistoli G, De Maddis D, Cipak A, *et al.* Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. *Free Radical Res* 2013; 47(Suppl. 1): 3–27.
11. Twarda-Clapa A, Olczak A, Białkowska AM, *et al.* Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors and diseases related to AGEs. *Cells* 2022; 11: 1312. <https://doi.org/10.3390/cells11081312>.
12. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signalling mechanisms in the pathogenesis of diabetes and its complications. *Ann N Y Acad Sci* 2011; 1243: 88–102.
13. Snelson M, Coughlan MT. Dietary advanced glycation end products: digestion, metabolism and modulation of gut microbial ecology. *Nutrients* 2019; 11(2): 215. <https://doi.org/10.3390/nu11020215>.
14. Birlouez-Aragon I, Saavedra G, Tessier FJ *et al.* A diet based on high heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. *Am J Clin Nutr* 2010; 91: 1220-1226.
15. Mark AB, Poulsen MW, Andersen S *et al.* Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. *Diabetes Care* 2014; 37: 88-95.
16. de Courten B, de Courten MP, Soldatos G *et al.* Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial. *Am J Clin Nutr* 2016; 103: 1426-33.
17. Uribarri J, Cai W, Ramdas M *et al.* Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. *Diabetes Care* 2011; 34: 1610-1616.
18. Luevano-Contreras C, Garay-Sevilla ME, Wrobel K *et al.* Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. *J Clin Biochem Nutr* 2013; 52: 22-26.
19. Macias-Cervantes MH, Rodriguez-Soto JMD, Uribarri J, *et al.* Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men. *Nutrition* 2015; 31: 446–451.
20. Baye E, de Courten MPJ, Walker K, *et al.* Effect of dietary advanced glycation end products on inflammation and cardiovascular risks in healthy overweight adults: a randomised crossover trial. *Sci Rep* 2017; 7: 4123. doi:10.1038/s41598-017-04214-6.
21. Vlassara H, Cai W, Goodman S *et al.* Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the anti-inflammatory AGE receptor-1. *J Clin Endocrinol Metab* 2009; 94: 4483-4491.
22. Harcourt BE, Sourris KC, Coughlan MT, *et al.* Targeted reduction of advanced glycation improves renal function in obesity. *Kidney Int* 2011; 80: 190–198.
23. Peppas M, Uribarri J, Cai W *et al.* Glycoxidation and inflammation in renal failure patients. *Am J Kidney Dis* 2004; 43: 690-695.
24. Semba RD, Gebauer SK, Baer DJ *et al.* Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. *J Nutr* 2014; 144: 1037-1042.
25. Vlassara H, Cai W, Crandall J *et al.* Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. *Proc Natl Acad Sci USA* 2002; 99: 15596-15601.
26. Negrean M, Stirban A, Stratmann B *et al.* Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. *Am J Clin Nutr* 2007; 85: 1236-1243.
27. Kellow NJ, Savige GS. Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review. *Eur J Clin Nutr* 2013; 67: 239-248.
28. Nowotny K, Schröter D, Schreiner M, *et al.* Dietary advanced glycation end products and their relevance for human health. *Ageing Res Rev* 2018; 47: 55-66.



### **p32-34 Dietary Advanced Glycation End-products (AGEs) and metabolic health – Cont'd**

29. National Health and Medical Research Council (2013) Australian Dietary Guidelines. *Australian Dietary Guidelines*. [online] Available at: [www.eatforhealth.gov.au/sites/default/files/content/n55\\_australian\\_dietary\\_guidelines.pdf](http://www.eatforhealth.gov.au/sites/default/files/content/n55_australian_dietary_guidelines.pdf) [Accessed 8 August 2022].
30. Hull GLJ, *et al.* *Food Chemistry* 2012; 131: 170-174
31. Lopez-Moreno J, Quintana-Navarro GM, Delgado-Lista J *et al.* Mediterranean diet reduces serum advanced glycation end products and increases antioxidant defenses in elderly adults: a randomized controlled trial. *J Am Geriatr Soc* 2016; 64: 901-904.

-- ENDS --